Thalidomide-PEG3-NH2

Background Introduction

Thalidomide-PEG3-NH2 is an advanced E3 ligase ligand-linker conjugate designed for the targeted protein degradation approach in chemical biology and drug discovery. By combining a thalidomide-based cereblon (CRBN) ligand with a flexible PEG3 linker and a terminal amine, this molecule serves as a crucial building block for PROTAC (Proteolysis Targeting Chimera) design. Its structure enables researchers to create bifunctional molecules that harness the ubiquitin-proteasome system for selective protein degradation, representing a transformative strategy in therapeutic development.

Mechanism

Thalidomide-PEG3-NH2 operates as a functional E3 ligase ligand-linker conjugate. The thalidomide moiety selectively binds to the CRBN E3 ubiquitin ligase, a key component of the body's cellular protein quality control machinery. The PEG3 linker provides optimal spacing and solubility, minimizing steric hindrance and enhancing the overall efficacy of PROTAC molecules. The terminal amine group allows for straightforward conjugation to target protein-binding ligands, yielding fully functional PROTACs. Upon administration, the resulting PROTAC molecule induces proximity between the target protein and the CRBN ligase complex, facilitating ubiquitination and subsequent proteasomal degradation of the target protein.

Applications

Thalidomide-PEG3-NH2 is primarily used in the synthesis of PROTACs for targeted protein degradation studies. It enables the rapid development of novel therapeutics for cancer, neurodegenerative diseases, and autoimmune disorders by facilitating the removal of disease-causing proteins. Researchers utilize this product for structure-activity relationship (SAR) studies, high-throughput screening, and the creation of bespoke PROTAC libraries. Its modular design streamlines the optimization of linker length and chemical properties, supporting advanced research in chemical biology, drug discovery, and next-generation therapeutics.

• Polyethylene glycol (PEG3) linker improves aqueous solubility and bioavailability in PROTAC applications.
• Amino-functionalized terminus enables versatile and efficient conjugation to target ligands or payloads.

Thalidomide-PEG3-NH2 serves as a versatile E3 Ligase Ligand-Linker Conjugate in PROTACs, facilitating targeted protein degradation by connecting a thalidomide-based ligand to a target protein ligand through a PEG3 linker. The following provides a detailed description of this molecule, focusing on the linker, ligand, and selection of target protein ligands.

Linker: This molecule incorporates a PEG3 linker, characterized by its moderate length and flexibility, which allows for optimal spatial arrangement between the ligand and the target protein. Its non-cleavable nature ensures stability throughout the degradation process.

Ligand: The ligand component is derived from thalidomide, a well-known E3 ligase recruiter. Its structural characteristics include a glutarimide ring, which is crucial for binding to the cereblon E3 ligase, enhancing the specificity and efficiency of the degradation process.

Reactive Site: The reactive site of the molecule is the terminal amine group, which couples effectively with carboxyl-containing target protein ligands. Recommended reaction types include amide bond formation, providing a robust and stable connection.

Recommended Target Protein Ligand: The ideal warhead for this molecule is a small molecule containing a carboxyl group, which allows for efficient coupling with the PEG3-NH2 linker. This compatibility ensures the formation of stable conjugates, facilitating the targeted degradation of proteins such as kinases or transcription factors, thereby advancing research in cellular regulation and disease mechanisms.